Humacyte director Kuznik awarded 125,000 stock options

The first 25% becomes exercisable on October 6, 2027, with the full award becoming vested on October 6, 2030.

Rhea-AI Filing Summary

Humacyte, Inc. (HUMA) director Paul Brian Kuznik acquired an award of 125,000 stock options to buy common stock on October 6, 2026. The options have an exercise price of $0.478 per share and expire October 6, 2036. After the award, he directly held 125,000 options; the first 25% becomes exercisable on October 6, 2027.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Kuznik Paul Brian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy) F1	125,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 125,000 contracts (Direct)

Footnotes (1)

1. F1. The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030.

Key Figures

Stock options awarded: 125,000 options Exercise price: $0.478 per share Options held directly after award: 125,000 options +4 more

7 metrics

Stock options awarded 125,000 options Award dated October 6, 2026

Exercise price $0.478 per share Options to buy common stock

Options held directly after award 125,000 options Following the October 6, 2026 award

Initial exercisable portion 25% Becomes exercisable October 6, 2027

Monthly exercisable portion 1/48 of the option Becomes exercisable on the 6th day of each month after the initial portion

Full vesting date October 6, 2030 Option becomes fully vested

Expiration date October 6, 2036 Stock options

Key Terms

Stock Options (right to buy), exercise price, exercisable

3 terms

Stock Options (right to buy) financial

"Stock Options (right to buy)"

exercise price financial

"exercise price of $0.478 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

exercisable financial

"becomes exercisable on October 6, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How do Paul Brian Kuznik’s HUMA stock options vest?

The first 25% becomes exercisable on October 6, 2027. After that, 1/48 of the option becomes exercisable on the 6th day of each month, with the option becoming fully vested on October 6, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 04:05 PM Accepted by SEC EDGAR 10/07/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kuznik Paul Brian

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.478	10/06/2026		A		125,000		(1)	10/06/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030.

	/s/ Paul B. Kuznik by Dale A. Sander as Attorney-in-Fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)